![Shay Shemesh](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Shay Shemesh
Gründer bei NUVECTIS PHARMA, INC.
Vermögen: 10 Mio $ am 31.05.2024
Aktive Positionen von Shay Shemesh
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
NUVECTIS PHARMA, INC. | Geschäftsführer | 27.07.2020 | - |
Gründer | 27.07.2020 | - | |
Corporate Officer/Principal | 27.07.2020 | - |
Karriereverlauf von Shay Shemesh
Ehemalige bekannte Positionen von Shay Shemesh
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
STEMLINE THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2015 | 01.01.2020 |
General Counsel | 01.01.2015 | 01.01.2020 | |
KERYX BIOPHARMACEUTICALS | Technik-/Wissenschafts-/F&E-Leiter | - | - |
Ausbildung von Shay Shemesh
Bar-Ilan University | Graduate Degree |
Statistik
International
Vereinigte Staaten | 3 |
2 | |
Israel | 2 |
Operativ
Chief Tech/Sci/R&D Officer | 2 |
Chief Operating Officer | 1 |
Founder | 1 |
Sektoral
Health Technology | 3 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 3 |
---|---|
Nuvectis Pharma, Inc. | |
Stemline Therapeutics, Inc.
![]() Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
Keryx Biopharmaceuticals, Inc.
![]() Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. | Health Technology |
- Börse
- Insiders
- Shay Shemesh
- Erfahrung